APA (7th ed.) Citation

Li, H., Liang, X., Qin, S., Chen, X., Huang, L., & Li, Y. First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Li, Huijuan, Xueyan Liang, Shiran Qin, Xiaoyu Chen, Liju Huang, and Yan Li. First-line Durvalumab Therapy Alone or in Combination with Tremelimumab for Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-effectiveness Analysis. Public Library of Science (PLoS).

MLA (9th ed.) Citation

Li, Huijuan, et al. First-line Durvalumab Therapy Alone or in Combination with Tremelimumab for Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-effectiveness Analysis. Public Library of Science (PLoS).